{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:11:48Z","timestamp":1698970308218},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":980,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:p>Laropiprant, a prostaglandin D<jats:sub>2<\/jats:sub> receptor\u20101 antagonist shown to reduce flushing symptoms, has been combined with niacin for treatment of dyslipidemia. This open\u2010label, randomized, 2\u2010period crossover study assessed the effects of laropiprant on the pharmacokinetics of digoxin, with 13 healthy subjects randomized to 2 treatments administered in random order with a 10\u2010day or longer washout period: (A) single\u2010dose digoxin 0.5 mg on day 1 and once\u2010daily oral doses of laropiprant 40 mg for 10 days beginning 5 days prior to digoxin dosing (day \u22125 to day 5); (B) single\u2010dose digoxin 0.5 mg on day 1. Blood was collected over the course of 120 hours post digoxin dose to assess pharmacokinetics of immunoreactive digoxin. Comparability was declared if the 90% confidence interval for the geometric mean ratio of laropiprant+digoxin to digoxin alone of the area under the plasma concentration\u2014time curve from time 0 to infinity (AUC<jats:sub>0\u2010\u221e<\/jats:sub>) for immunoreactive digoxin fell within 0.80 to 1.25. The AUC<jats:sub>0\u2010\u221e<\/jats:sub> and maximum observed plasma concentration (C<jats:sub>max<\/jats:sub>) geometric mean ratios of immunoreactive digoxin were 0.91 (90% confidence interval, 0.76\u20131.10) and 1.04 (90% confidence interval, 0.91\u20131.21), respectively. Median time of occurrence of C<jats:sub>max<\/jats:sub> and mean half\u2010life of immunoreactive digoxin were comparable in the presence and absence of laropiprant. Coadministration of digoxin and laropiprant was generally well tolerated. The small decrease in exposure to immunoreactive digoxin (\u223c10%) following coadministration of laropiprant and digoxin is not considered to be clinically meaningful.<\/jats:p>","DOI":"10.1177\/0091270009356571","type":"journal-article","created":{"date-parts":[[2010,3,3]],"date-time":"2010-03-03T03:04:24Z","timestamp":1267585464000},"page":"823-828","source":"Crossref","is-referenced-by-count":1,"title":["Effects of Laropiprant, a Selective Prostaglandin D<sub>2<\/sub> Receptor 1 Antagonist, on the Steady\u2010State Pharmacokinetics of Digoxin in Healthy Adult Subjects"],"prefix":"10.1002","volume":"50","author":[{"given":"Fang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Vessey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa","family":"Wenning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Buckland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy O.","family":"Johnson\u2010Levonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Denker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2005.01528.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-000-0096-y"},{"key":"e_1_2_6_4_2","first-page":"229","article-title":"Increasing HDL cholesterol with extended\u2010release nicotinic acid: from promise to practice","volume":"62","author":"Birjmohun RS","year":"2004","journal-title":"Neth J Med"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00732-2"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-3-4"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(89)90088-9"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12499963"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)92627-1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.170"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700586"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601574103"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.030833"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250601175565"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100180"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.03.058"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm0603668"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.10.023"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.011551"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.014696"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100345"},{"key":"e_1_2_6_22_2","first-page":"1","volume-title":"Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring","author":"Reuning RH","year":"1992"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/17482940902883246"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199109000-00001"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.22.2444"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.195"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.21.7735"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.02.008"},{"key":"e_1_2_6_29_2","first-page":"591","article-title":"Study on the interaction of the dopamine agonist alpha\u2010dihydroergocryptine with the pharmacokinetics of digoxin","volume":"50","author":"Retzow A","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004268048"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0003-z"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270009356571","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270009356571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T19:39:38Z","timestamp":1698953978000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270009356571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1177\/0091270009356571"],"URL":"https:\/\/doi.org\/10.1177\/0091270009356571","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}